Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs.
Read More
The company is getting ready only that it wants to stay within the legal framework and ensure it plays the right way.
Read More
The research and data are important for both consumers and the industry with the explosive growth of interest in cannabinoids coming into the mainstream.
Read More
The Company expects to report topline results from this study in the summer of 2020. These data are anticipated to support an initial marketing application for lenabasum.
Read More
The community has warmly received the launch of Epidiolex, the first prescription pharmaceutical formulation of highly purified CBD in the U.S. for seizures associated with LGS or Dravet syndrome.
Read More
Get stock alerts, news & related alerts straight to your inbox!